Novartis has experienced a major late-stage Phase III trial setback for its drug del-desiran in the Harbor trial, according to the company.
Further verified details about the nature of the setback were not immediately available.
Novartis Suffers Phase III Trial Setback for Del-Desiran
Novartis reported a major late-stage setback in the Harbor trial for its investigational drug del-desiran.
PA
Priya Anand · Equities & Earnings Desk · 13 Sept 2026 · 20:38 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
